Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Medication Development Research.
Date: November 2, 2000.
Time: 10 am to 12 pm.
Agenda: To review and evaluate grant applications.
Place: Hyatt—Arlington at Washington's Key Bridge, 1325 Wilson Boulevard, Arlington, VA 22209-9990.
Contact Person: Mark Swieter, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1389.
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Medication Development Research.
Date: November 2, 2000.
Time: 12:30 pm to 1:30 pm.
Agenda: To review and evaluate grant applications.
Place: Hyatt—Arlington at Washington's Key Bridge, 1325 Wilson Boulevard, Arlington, VA 22209-9990.
Contact Person: Mark Swieter, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1389.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Program, National Institutes of Health, HHS)
Dated: September 29, 2000.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 00-25885 Filed 10-06-00; 8:45 am]
BILLING CODE 4140-01-M